After Ozempic: The Next Wave of Weight Loss Drugs Explained
Semaglutide was a breakthrough. Tirzepatide improved on it. But the pipeline of GLP-1 class medications does not stop there. Three compounds, retatrutide, orforglipron, and maritide, represent the next generation of weight loss pharmacology. Each takes a different approach to improving on what semaglutide started, and understanding the differences helps you anticipate where this field is heading and what options might be available to you in the near future.
Dr. G from Lifestyle Medicine breaks these three down clearly, and the picture that emerges is a field moving toward more effective, more convenient, and potentially safer weight loss medications.
Retatrutide: The Triple Agonist
Retatrutide is the most aggressive approach in the pipeline. Where semaglutide hits one receptor (GLP-1) and tirzepatide hits two (GLP-1 and GIP), retatrutide hits three: GLP-1, GIP, and the glucagon receptor. That third receptor makes a real difference in the mechanism and the results.
Glucagon is a hormone that raises blood sugar by telling the liver to release stored glucose. It also increases energy expenditure and promotes fat breakdown. Activating the glucagon receptor alongside GLP-1 and GIP means retatrutide reduces appetite (via GLP-1 and GIP) while simultaneously increasing how many calories your body burns at rest (via glucagon). This dual approach, eating less and burning more, is theoretically more effective than appetite suppression alone.
The Phase 2 trial data supports this theory. Participants on the highest dose of retatrutide lost an average of 24.2 percent of their body weight over 48 weeks. That is roughly 9 percentage points more than semaglutide achieves and about 2 points more than tirzepatide. On a 250-pound person, that is a loss of about 60 pounds, landing at 190.
Perhaps more significant than the average is the upper range. Some participants in the trial lost over 30 percent of their body weight. That level of weight loss approaches what bariatric surgery achieves, which has led to the provocative question of whether medications could eventually replace surgical intervention for many patients.
The glucagon activation also raises a theoretical benefit for lean mass preservation. By increasing energy expenditure, the body may rely less on breaking down muscle protein for fuel during weight loss. This has not been confirmed with body composition data yet, but the mechanism suggests retatrutide might produce a better fat-to-muscle loss ratio than GLP-1-only drugs.
The Trade-offs
More receptor activation means more potential for side effects. The GI side effects in the retatrutide trial were similar to other GLP-1 medications: nausea, diarrhea, vomiting, and constipation. But the glucagon component introduces additional considerations. Glucagon raises blood sugar, which could complicate use in people with diabetes. The GLP-1 and GIP components counteract this to some degree, but managing the balance between three hormonal signals is more complex than managing one or two.
Heart rate increases were observed in some participants, which is a known effect of glucagon receptor activation. These were generally mild and not clinically significant in the trial, but they will need careful monitoring in larger Phase 3 studies.
Retatrutide is currently in Phase 3 trials, with results expected in 2026 or early 2027. If approved, it would likely become the most effective weight loss medication available, though the triple-agonist approach also means more unknowns about long-term safety compared to simpler GLP-1-only drugs.
Orforglipron: The GLP-1 Pill
Orforglipron represents a completely different kind of advance. It is not a new mechanism. It is the same GLP-1 receptor agonism that semaglutide provides. The innovation is in the delivery: orforglipron is a small molecule taken as a daily pill rather than a weekly injection.
This distinction matters more than it might seem. Many people who could benefit from GLP-1 therapy are deterred by injections. Needle phobia is common. The injection process, including reconstitution for some formulations, cold storage, and the ritual of a weekly shot, creates barriers to adherence. A daily pill eliminates all of that.
The Phase 2 trial showed weight loss of about 14.7 percent at the highest dose over 36 weeks. That is slightly lower than semaglutide is injection form, which is expected since oral bioavailability is always a challenge with peptide-like molecules. But 14.7 percent weight loss from a daily pill is still a remarkable result that would have been unimaginable a decade ago.
The side effect profile was similar to injectable GLP-1 medications. Nausea was the most common complaint. One potential advantage of daily dosing is that the steady-state drug levels may produce more consistent appetite suppression with fewer peaks and troughs compared to weekly injections. Some patients on weekly semaglutide report that appetite suppression wears off toward the end of the week before their next injection. A daily pill could smooth out that pattern.
Why Small Molecules Matter for Access
Injectable peptides are expensive to manufacture, require cold chain storage, and have limited shelf life. Small molecule drugs like orforglipron are cheaper to produce, stable at room temperature, and have the manufacturing scalability that the world needs to make GLP-1 therapy accessible beyond wealthy countries and well-insured patients.
If orforglipron is approved and priced significantly below injectable semaglutide, it could democratize access to effective weight loss medication. The global obesity epidemic cannot be addressed by drugs that cost $1,000 per month. A daily pill that costs a fraction of that, even if somewhat less effective, could reach far more people.
Maritide: The Long-Acting Amylin Play
Maritide takes yet another approach. It combines amylin receptor agonism with GLP-1 receptor agonism in a single molecule. Amylin is a hormone co-secreted with insulin from the pancreas that independently reduces appetite, slows gastric emptying, and suppresses glucagon secretion.
The amylin component adds a mechanism that GLP-1 alone does not provide. Amylin receptors are concentrated in the area postrema of the brain, a region involved in nausea and satiety that is distinct from where GLP-1 primarily acts. By hitting both targets, maritide may produce stronger appetite suppression through complementary brain pathways.
The real innovation with maritide is its dosing frequency. It is designed as a monthly injection, which would make it the most convenient injectable in the class. Going from weekly injections to monthly significantly reduces the treatment burden and could improve long-term adherence.
Early clinical data from the Phase 2 trial showed promising weight loss, though complete results are still emerging. The monthly dosing was well-tolerated, and the pharmacokinetic profile supported consistent drug levels throughout the dosing interval.
The Combination Therapy Future
One development Dr. G highlights that gets less attention than the individual drugs is the potential for combination therapy. Just as tirzepatide combined two receptor targets into one molecule, future approaches may involve combining separate medications that work through entirely different mechanisms.
For example, a GLP-1 agonist combined with a SGLT2 inhibitor (a class of drug currently used for diabetes that causes glucose and calorie excretion through urine) could produce weight loss from two independent mechanisms. Some clinicians are already using this combination off-label with promising results. A GLP-1 agonist combined with a selective androgen receptor modulator (SARM) could theoretically promote fat loss while actively preserving or building muscle, addressing the lean mass loss problem that plagues current medications.
The pharmaceutical pipeline also includes combinations at the molecular level. Survodutide, a dual glucagon/GLP-1 agonist from Boehringer Ingelheim, takes a similar approach to retatrutide but with a different receptor activation ratio. Pemvidutide, another dual agonist, is being developed with a specific focus on liver fat reduction for non-alcoholic steatohepatitis (NASH).
For patients, this expanding pipeline means that if the first medication you try does not work well enough or causes intolerable side effects, the list of alternatives is growing rapidly. The era of one-size-fits-all weight loss pharmacology is ending, replaced by a toolkit of medications that can be matched to individual metabolic profiles, tolerance patterns, and treatment goals.
Practical Considerations for Timing Your Treatment
The question patients ask most frequently is whether they should start treatment now with available medications or wait for the newer options. Dr. G is answer is nuanced. If your BMI is above 35 and you have obesity-related health conditions, the health risks of waiting outweigh the potential benefits of a slightly more effective future medication. Every month spent in severe obesity increases your cumulative cardiovascular, metabolic, and joint damage.
If your situation is less urgent, meaning a BMI of 30 to 35 without significant comorbidities, starting with currently available options is still reasonable. You can always switch to a newer medication when it becomes available. Starting treatment now builds healthy habits around diet, exercise, and medication adherence that transfer to any future medication change.
The insurance landscape should factor into your timing decision. Newer medications often have limited insurance coverage in their first year on the market, and pricing may start high before competition and formulary negotiations bring it down. Starting with a well-covered current medication and switching when the newer option becomes affordable and accessible is a practical approach for cost-conscious patients.
What This Pipeline Means for You
If you are starting GLP-1 therapy today, semaglutide and tirzepatide are your options, and they are both effective. You are not making a mistake by starting now rather than waiting for the next generation.
If you have tried semaglutide or tirzepatide and either plateaued or could not tolerate the side effects, the pipeline gives you genuine reasons for optimism. Within the next one to three years, you are likely to have access to a triple agonist (retatrutide) that produces greater weight loss, a daily pill (orforglipron) that eliminates injections, and a monthly injection (maritide) that reduces treatment frequency.
If cost is your primary barrier, orforglipron could be the most impactful development. The economics of small molecule manufacturing are fundamentally different from biological peptides, and the price point could make effective weight loss medication accessible to millions of people currently priced out.
Keep an eye on the Phase 3 trial results for all three compounds. The data that emerges over the next 12 to 24 months will determine which of these reaches the market first and how they stack up against the medications already available. Your doctor can help you evaluate whether switching to a newer option makes sense once they become available.